1.3 Harms and benefits of testing Study ref Design LoE N Aim, setting, population, measurements Results Comments () Cohort III-2 946 To examine whether women with an were higher rates of adverse outcomes Aim: HbA1c of 41–49 mmol/mol (5.9–6.6%) are at in the Later group than the Other GDM group higher risk than women with an HbA1c of (pre-eclampsia 8.0 vs 2.4%, P=0.001, preterm <41 mmol/mol (5.9%) and whether pregnancy birth 16.6 vs 8.2%, P=0.002, neonatal outcomes are improved if treated at <24 admission 15.5 vs 9.2%, P=0.02). weeks’ gestation. Outcomes were similar between the Early Setting: New Zealand group and Other GDM group (pre-eclampsia 1.5 vs 2.4%, P=0.5, preterm birth 10.5 vs 8.2% Women with diabetes in Population: P=0.4, neonatal admission 13.6 vs 9.2%, pregnancy diagnosed by early HbA1c testing P=0.12). or subsequent OGTT at <34 weeks’ gestation Comparing the Early and Later groups, the Methods: Data were extracted from the Early group had less pre-eclampsia, 1.5 vs hospital database. Women with HbA1c 8.0%, adjusted P=0.03. Other outcomes were 41–49 mmol/mol (5.9–6.6%) were divided into not statistically different. those seen <24 weeks (Early, n=134) and those seen 24 weeks (Later, n=151). Those with ≥ HbA1c < 41 mmol/mol (5.9%) were labelled Other GDM (n=661). 1.4 Uptake of HbA1c compared to glucose challenge test and oral glucose tolerance test Study ref Design LoE N Aim, setting, population, measurements Results Comments
1.3 Harms and benefits of testing Study ref Design LoE N Aim, setting, population, measurements Results Comments () Cohort III-2 946 Aim: To examine whether women with an HbA1c of 41–49 mmol/mol (5.9–6.6%) are at higher risk than women with an HbA1c of <41 mmol/mol (5.9%) and whether pregnancy outcomes are improved if treated at <24 weeks’ gestation. Setting: New Zealand Population: Women with diabetes in pregnancy diagnosed by early HbA1c testing or subsequent OGTT at <34 weeks’ gestation Methods: Data were extracted from the hospital database. Women with HbA1c 41–49 mmol/mol (5.9–6.6%) were divided into those seen <24 weeks (Early, n=134) and those seen ≥ 24 weeks (Later, n=151). Those with HbA1c < 41 mmol/mol (5.9%) were labelled Other GDM (n=661). were higher rates of adverse outcomes in the Later group than the Other GDM group (pre-eclampsia 8.0 vs 2.4%, P=0.001, preterm birth 16.6 vs 8.2%, P=0.002, neonatal admission 15.5 vs 9.2%, P=0.02). Outcomes were similar between the Early group and Other GDM group (pre-eclampsia 1.5 vs 2.4%, P=0.5, preterm birth 10.5 vs 8.2% P=0.4, neonatal admission 13.6 vs 9.2%, P=0.12). Comparing the Early and Later groups, the Early group had less pre-eclampsia, 1.5 vs 8.0%, adjusted P=0.03. Other outcomes were not statistically different. 1.4 Uptake of HbA1c compared to glucose challenge test and oral glucose tolerance test Study ref Design LoE N Aim, setting, population, measurements Results Comments
Detecting%20undiagnosed%20diabetes%20evidence%20evaluation%2016May17.docx